Dibutyryl cAMP Influences Endothelial Progenitor Cell Recruitment During Wound Neovascularization  by Asai, Jun et al.
Dibutyryl cAMP Influences Endothelial Progenitor
Cell Recruitment During Wound Neovascularization
Jun Asai1, Hideya Takenaka1, Norito Katoh1 and Saburo Kishimoto1
Delayed wound healing is one of the major complications of diabetes, and is caused by delayed cellular
infiltration, reduced angiogenesis, and decreased formation and organization of collagen fibers. Recently,
endothelial progenitor cells (EPC) isolated from peripheral blood were shown to accumulate at sites of
neovascularization during wound healing. The present study tested the hypothesis that sodium N-6,20-O-
dibutyryl adenosine-30,50-cyclic phosphate (DBcAMP), which has been shown to accelerate wound healing,
promotes recruitment of EPC into wounds and contributes to the stimulation of neovascularization in
genetically diabetic mice. Topical application of DBcAMP resulted in significant acceleration of wound healing
and wound vascularization partly via enhanced recruitment of EPC. EPC in DBcAMP-treated wounds were
mainly localized to cell clusters at the border of the granulation tissue, a site where blood supply is most
insufficient. DBcAMP treatment increased the mRNA expression of angiogenic cytokines vascular endothelial
growth factor (VEGF) and stromal cell-derived factor-1a (SDF-1a) in vivo in wound tissue and in cultured
fibroblasts and macrophages, in vitro. Culture supernatants of DBcAMP-treated cells enhanced EPC migration.
Taken together, these results indicate that DBcAMP promotes neovascularization in wound healing, at least
partly by increasing the accumulation of EPC at wound sites.
Journal of Investigative Dermatology (2006) 126, 1159–1167. doi:10.1038/sj.jid.5700188; published online 2 March 2006
INTRODUCTION
Impaired wound healing is one of the major clinical problems
in patients with diabetes (Jeffcoate and Harding, 2003). Poor
healing of diabetic wounds is characterized by impaired
angiogenesis and diminished formation of the granulation
tissue. Of these, angiogenesis is considered to play a pivotal
role, as it is required for successful wound repair.
In the postnatal period, neovascularization was previously
thought to result only from the proliferation and migration
of pre-existing, fully differentiated endothelial cells resi-
ding within the vessels, a process termed ‘‘angiogenesis’’
(Folkman and Shing, 1992; Risau, 1995). Recently, however,
endothelial progenitor cells (EPC) have been isolated from
peripheral blood cells, and have been shown to undergo
incorporation into new vessels in ischemic regions (Asahara
et al., 1997; Badiavas et al., 2003; Tepper et al., 2005).
This is a process consistent with ‘‘vasculogenesis’’, a critical
mechanism for establishing the primordial vascular network
in the embryo (Asahara et al., 1997). Previous studies
demonstrated that transplantation of ex vivo-expanded EPC
improved the recovery of blood flow and capillary density in
a murine hindlimb ischemia model by promoting vasculo-
genesis (Kalka et al., 2000). Furthermore, topical application
of vascular endothelial growth factor (VEGF) protein to
cutaneous wounds has been shown to increase neovascular-
ization by mobilizing and recruiting EPC (Galiano et al.,
2004). These findings suggest that not only angiogenesis but
also vasculogenesis may play a major role in the process of
neovascularization during adult wound healing.
Sodium N-6,20-O-dibutyryl adenosine-30,50-cyclic phos-
phate (DBcAMP) is an analog of cAMP, which promotes
the production of several cytokines, including IL-6, IL-8, and
transforming growth factor-b, by keratinocytes and fibro-
blasts, as well as stimulating the growth of these cells (Zhou
and Ono, 2000; Onuma et al., 2001; Takahashi et al., 2004).
In Japan, an ointment that contains DBcAMP (ActosinTM
ointment; Daiichi Pharmaceutical Co., Ltd, Tokyo, Japan) has
been widely used to treat impaired skin ulcers. Clinical
studies have shown the favorable effects of DBcAMP on
impaired skin ulcers, such as diabetic foot ulcers or decubitus
(Kimura et al. (Kimura Y, Suwa M, Sano T, Yamaguchi Y,
Yamada A (1997) Post marketing surveillance of bucladesine
(DBcAMP) ointment for chronic skin ulcers in Japan. Aust J
Dermatol 38(Suppl 2): 245; Second Joint Meeting of the
Wound Healing Society and European Tissue Repair Society,
1996), Miyagi et al. (Miyagi T, Nonaka S, Kimura Y,
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Yamaguchi Y, Yamada A (1997) Safety and efficacy of
bucladesine (DBcAMP) ointment in its long-term use for
patients with pressure sore in Okinawa District of Japan: an
preliminary report. Aust J Dermatol 38(Suppl 2): 246; Second
Joint Meeting of the Wound Healing Society and European
Tissue Repair Society, 1996), Takehara et al. (Takehara K,
Kawara S, Kimura Y, Yamaguchi Y, Yamada A (1997) Long-
term safety and efficacy of bucladesine (DBcAMP) ointment
in patients with decubitus in Hokuriku District of Japan: an
interim report. Aust J Dermatol 38(Suppl 2): 246; Second Joint
Meeting of the Wound Healing Society and European Tissue
Repair Society, 1996)); however, the mechanism by which
DBcAMP influences neovascularization during cutaneous
wound healing has not been defined clearly.
In the present study, we show that in an established
model of diabetes-associated delayed wound healing (Tsuboi
et al., 1992), DBcAMP treatment leads to an enhanced
recruitment of EPC and to significant upregulation of
angiogenic growth factors, thereby significantly accelerating
wound healing via processes involving both angiogenesis
and vasculogenesis.
RESULTS
DBcAMP accelerates healing and neovascularization of diabetic
wounds
To investigate the effects of DBcAMP on wound closure, we
created full-thickness skin wound on the dorsal skin of
C57BL/KsJ-db/db (db/db) mice, and applied DBcAMP or
saline every second day. On day 14 (Figure 1a), DBcAMP-
treated wounds showed more than 90% epithelialization,
whereas less than 50% of the wound was epithelialized in the
control group. Significantly smaller wound areas were
observed in DBcAMP-treated mice both on days 7 and 14
with maximal difference observed on day 14 (Figure 1b; %
wound closure on day 7 in the control versus DBcAMP
group: 13.3171.48 vs 49.5076.89%, Po0.0001; on day 14:
36.0974.74 vs 96.8371.61%, Po0.0001, Figure 1b).
Hematoxylin and eosin staining showed thick granulation
tissue and re-epithelialization in the DBcAMP-treated
wounds; however, thin granulation tissue was found in the
wounds of control group (Figure 1c). Several blood vessels
were observed in the granulation tissue of DBcAMP-treated
wound; however, vessels were scarcely observed in saline-
treated wounds. The histological scores of wounds treated
with DBcAMP were significantly higher than those for the
control group (day 7 in the control versus DBcAMP group:
2.070.45 vs 5.270.49, Po0.0001; day 14: 4.870.37 vs
11.670.25, Po0.0001, Figure 1d).
As the healing of skin wounds requires neovascularization,
we next evaluated vascularity of wound granulation tissue.
Wound angiogenesis was analyzed by immunostaining of
10-mm frozen sections for endothelial lineage marker CD31,
to visualize neovascularization. We also evaluated the func-
tional vessels by perfusion with Rhodamine-conjugated BS1
lectin, which is one of the established endothelial markers
and stains endothelial cells lining the perfused vasculature (Ii
et al., 2005). Neovascularization at the margin of saline or
DBcAMP-treated wounds in diabetic mice on days 7 (Figure
2a) and 14 (Figure 2b). DBcAMP treatment significantly
enhanced the number of total vessels (CD31þ , green
fluorescence) as well as the number of functional blood
vessels (BS1 lectinþ , red fluorescence). Additionally, signi-
ficantly higher CD31þ BS1 lectin cells suggested an
enhanced neovascularization including recruitment of EPC
into the DBcAMP-treated wounds (merge images; green
fluorescence). Furthermore, DBcAMP treatment led to the
formation of larger and thicker vessels growing widely in
the center of the wound at day 14 (Figure 2b), whereas in the
control group, only small, narrow new vessels were observed
at the wound margin. Thus, DBcAMP significantly enhanced
wound vascularity, as assessed by the % fluorescent area
of CD31 (day 7 in the control versus DBcAMP group:
3.5270.67 vs 7.0271.20%, Po0.05; day 14: 7.6071.17 vs
15.6071.12%, Po0.002, Figure 2c).
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Figure 1. Effect of DBcAMP on full-thickness skin wound closure in
genetically diabetic mice. DBcAMP or saline was applied on the wound.
(a) Macroscopic appearance of wounds receiving different treatments. (b) %
wound closure. DBcAMP significantly accelerated wound closure compared
with the control (n¼5 per group, *Po0.001 vs control). (c) Effect of DBcAMP
on wound histology at day 14. Photomicrographs show hematoxylin and
eosin-stained sections. An improved wound appearance and increased
granulation tissue are observed in the DBcAMP-treated wound. The wound
bed shows a thin layer of granulation tissue over adipose tissue in the control
group. The wound bed shows a thick layer of granulation tissue covered with
epithelium in the DBcAMP group. In higher magnifications, functional
neovessels are found in the granulation tissue of DBcAMP-treated wound
(arrow), but scarcely in control. (d) Histological score. The DBcAMP group
had a significantly higher histological score compared with the control group
(n¼5 per group, *Po0.001 vs control).
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DBcAMP treatment increases the recruitment of EPCs into the
wounds
As CD31þ staining may represent capillaries, resident
mature endothelial cells as well as recruited EPCs, in
the next series of experiments, we evaluated the specific
contribution of circulating EPCs to wound neovascularization
using an ex vivo-expanded EPC transplantation model. Ex
vivo-expanded EPCs, labeled with 1,10 – dioctadecyl –
3,3,30^30 – tetramethylindocarbocyanine for tracking, were
intravenously injected into the tail vein of mice immediately
following the creation of a full-thickness dorsal skin wound in
db/db mice. Seven days after wounding and EPC transplanta-
tion, mice were killed and their wounds were harvested. To
visualize blood vessels in the healing wound, frozen sections
were subjected to CD31 staining. Figure 3a–h shows the
contribution of circulating EPC to the development of the
wound vasculature on day 7. Green fluorescence indicates
CD31þ capillaries and red indicates transplanted EPC,
whereas double-positive cells are circulating EPC that have
differentiated into vessel wall components. EPC were mainly
located at the edge of the wound. EPC recruitment into the
wounds of the DBcAMP group was significantly increased
compared with that in the control group (12.1572.21 vs
72.075.49 cells/mm2 for control versus DBcAMP group,
Po0.0001, Figure 3i).
DBcAMP upregulates VEGF and SDF-1a production
To identify the mechanisms responsible for the influence of
DBcAMP on EPC recruitment, we evaluated the mRNA levels
for VEGF and stromal cell-derived factor-1 (SDF-1) a, both of
which are chemokines known to enhance EPC homing and
function, in vivo. Skin tissues were harvested at days 1, 4, and
7 after wounding and assessed for VEGF and SDF-1a mRNA
levels by quantitative PCR. Both VEGF (Figure 4a) and SDF-
1a (Figure 4b) transcripts were upregulated by wounding
in both groups. However, upregulation of VEGF and SDF-1a
in DBcAMP-treated wound were significantly greater than
saline-treated wound.
Immunohistochemically, VEGF was colocalized with both
F4/80þ cells, which represent macrophages, and F4/80
cells, which may include EPCs as well as mesenchymal cells
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Figure 2. Effect of DBcAMP on the vascularity of granulation tissues at the
wound margin. (a, b) Sections immunostained for CD31 (green) show
neovascularization at the wound margin after 7 days (a) or 14 days (b).
Labeling of functional vessels was performed by injection of Rhodamine-
conjugated BS1 lectin (red) before killing. CD31þ and BS1 lectin area
(green fluorescent in merged image) indicate newly formed neovessels or
infiltrating CD31þ cells, which include EPCs. At day 7, several CD31þ (and
BS1 lectin) cells are observed in the granulation tissue of DBcAMP-treated
wound; however, scarcely observed in control wound (a). There are tiny and
narrow new vessels at the wound margin in the control group, whereas larger
and thicker vessels are growing widely in the center of the wound in the
DBcAMP group at day 14. Original magnification 100. Bar¼ 100mm.
(c) Percent fluorescent area. DBcAMP significantly enhanced the vascularity
of wounds (n¼5 per group, *Po0.05 vs control, **Po0.002 vs control).
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Figure 3. Contribution of EPC at the wound edge. (a–h) Representative
photomicrographs of the immunostained wound edge at 7 days after creation.
Red fluorescence identifies DiI-labeled EPC (a, b, e, f) and green fluorescence
indicates CD31þ cells (endothelial cells) (c, g). Double-positive cells are EPC
that have differentiated into cells forming the new vessels (d, h). (i) EPC
recruitment into granulation tissue was significantly increased in the DBcAMP
group compared with the control group (n¼ 5 per group, *Po0.001 vs
control). Bar¼ 100 mm.
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such as fibroblasts (Figure 4c). SDF-1a was also stained in
both F4/80þ and F4/80 cells (Figure 4d).
We chose primary cultured adult diabetic dermal fibro-
blasts and macrophages, which are two cell types contribut-
ing to neovascularization during wound healing by releasing
angiogenic factors (Singer and Clark, 1999), for in vitro
studies (Figure 5). As expected, VEGF mRNA level was
downregulated in both fibroblasts and macrophages under
high glucose culture condition (35 mM). DBcAMP upregu-
lated VEGF mRNA in a dose-dependent manner, and the
repression of VEGF transcript under high glucose condition
was reversed by supplementation of 105 M of DBcAMP
(Figure 5a). The secreted VEGF protein level in supernatants
harvested from cultured fibroblasts or macrophages was
also increased by the addition of DBcAMP to the cultures
(Figure 5b). SDF-1a transcript in macrophages, but not in
the fibroblasts, was upregulated at 6 hours after the addition
of DBcAMP (Figure 6a). After 24 hours, however, SDF-1a
mRNA was also upregulated in fibroblasts (Figure 6a). We
also evaluated the SDF-1a protein levels in supernatants
harvested from cultured fibroblasts or macrophages. SDF-1a
level in fibroblasts supernatant was increased by the addition
of DBcAMP (Figure 6b); however, SDF-1a level in macro-
phages was lower than the detection limit of assay
(o0.069 ng/ml, data not shown).
DBcAMP indirectly promotes EPC migration
To assess the migratory activity of EPC, 10 ng/ml of VEGF
or SDF-1a was used as a chemotactic agent. The migratory
response of EPC exposed to conditioned medium (CM) from
fibroblasts or macrophages treated with different doses of
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Figure 4. Effect of DBcAMP on VEGF and SDF-1a expression in wound.
(a, b) Quantitative RT-PCR of VEGF (a) and SDF-1a (b). Skin samples were
harvested at indicated times and subjected to RT-PCR analysis. Topical
application of DBcAMP (102 M) upregulates VEGF expression at each time
point (a). SDF-1a expression was upregulated by DBcAMP at days 4 and 7 (b)
(n¼5 per group, *Po0.05, **Po0.02 vs saline). (c, d) Immunofluorescence
staining of macrophage marker, F4/80 and VEGF (c) or SDF-1a (d) in wound
granulation tissues 7 days after wounding. Both F4/80þ cells (macrophages)
and F4/80 cells (including mesenchymal cells) showed VEGF and SDF-1a
expression. Bar¼50 mm.
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Figure 5. Effect of DBcAMP on VEGF mRNA and protein expression in
fibroblasts and macrophages. (a) Quantitative RT-PCR. Six hours or 24 hours
after adding DBcAMP to the culture medium (0, 106, 105, 104 M) with low
(5 mM) or high (35 mM) glucose condition. VEGF transcript is decreased in
high-glucose condition. DBcAMP upregulates VEGF mRNA in both fibro-
blasts and macrophages in a dose-dependent manner (*Po0.05, **Po0.001,
***Po0.0001). (b) ELISA for mouse VEGF. Samples are harvested 48 hours
after DBcAMP treatment with low or high glucose condition. Addition of
DBcAMP increased VEGF secretion by both fibroblasts and macrophages
(*Po0.05, **Po0.001, ***Po0.0001). Mean7SEM (n¼ 3). Data are
representative of three independent experiments.
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DBcAMP was measured by a modified Boyden chamber
migration assay (Figure 7). The number of migrated EPC
treated with high-glucose-conditioned CM were significantly
decreased compared with low-glucose-conditioned CM;
however, both types of CM induced a statistically significant
increase of EPC migration when DBcAMP was included in
the medium. Enhanced migration in response to DBcAMPþ
CM from fibroblasts was significantly attenuated in the
presence of anti-VEGF- and anti-SDF-1a-blocking antibodies
(Figure 7a). On the other hand, the effect of DBcAMPþCM
from macrophages was attenuated only by blockade of VEGF,
but not of SDF-1a (Figure 7b).
DISCUSSION
DBcAMP induces various biological effects, including cell
proliferation, differentiation, and migration. Previous reports
indicate that these effects are mediated by a modulation in
mitogen-activated protein kinase activity through protein
kinase A-dependent pathway (Cheng et al., 1998; Pueyo
et al., 1998; Zhou and Ono, 2000; Onuma et al., 2001;
Takahashi et al., 2004).
As delayed wound healing in diabetics is caused by
cellular dysfunction and impairment of growth factor
production (Lerman et al., 2003), favorable effects of
DBcAMP on diabetic wound healing are suggested. In this
study, topical administration of DBcAMP to diabetic wound
significantly promoted granulation tissue formation and re-
epithelialization compared with the control. These findings
experimentally endorse the stimulatory effects of DBcAMP on
impaired wound healing.
The healing of skin wounds requires neovascularization.
Previous studies have shown that neovascularization is
impaired in diabetes (Jeffcoate and Harding, 2003; Lerman
et al., 2003). Our observations of enhanced vascularity in the
DBcAMP-treated diabetic wounds and subsequent acceler-
ated wound healing suggest that both increased neovascular-
ization and re-epithelialization as a target for DBcAMP
effects. The present study also shows that topical application
of DBcAMP to diabetic wounds increases the recruitment of
EPC in the granulation tissue and that EPC primarily localize
at the border of the granulation tissue, a site where blood
supply is the most insufficient, and thus neovascularization
most required. Recent studies have shown that recruitment of
EPC in regenerating vasculature is in part mediated by a
hypoxic gradient via the enhanced expression of proangio-
genic factors like SDF-1 or VEGF (Ceradini et al., 2004;
Tepper et al., 2005), which, subsequently, mobilize EPC from
the bone marrow and homed to the ischemic sites. Under
hypoxic conditions such as in wounds, EPC are stimulated to
form organized cell clusters, which then form cord-like
vascular structures. These vascular cords undergo canaliza-
tion and connect to existing vessels (Tepper et al., 2005).
These reports are consistent with our present findings in
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Figure 6. Effect of DBcAMP on SDF-1a mRNA and protein by macrophages
and fibroblasts. (a) Quantitative RT-PCR. Six hours or 24 hours after adding
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(35 mM) glucose condition. SDF-1a mRNA is upregulated at 6 h in
macrophages but not in fibroblasts. However, SDF-1a mRNA in fibroblasts is
upregulated at 24 hours after adding DBcAMP. (b) ELISA for mouse SDF-1a.
Samples are harvested 48 hours after DBcAMP treatment with low or high
glucose condition. Addition of DBcAMP increased SDF-1a secretion by
both fibroblasts (*Po0.05, **Po0.005). Mean7SEM (n¼3). Data are
representative of three independent experiments.
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Figure 7. DBcAMP indirectly induces EPC migration. (a, b) The migratory
response of EPC to CM from cultured fibroblasts (a) or macrophages (b) treated
with different doses of DBcAMP was measured with a modified Boyden
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***Po0.0001). Mean7SEM (n¼3). Data are representative of three
independent experiments.
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DBcAMP-treated wounds. Only a few EPC were found in the
granulation tissue of control wounds. Previous studies have
also shown that tissue VEGF levels are decreased in diabetics
(Lerman et al., 2003), and EPC from diabetics show
functional impairment (Tepper et al., 2002). Our data of
delayed wound healing in diabetic mice is thus in accor-
dance with these studies. Homing of circulating EPC to the
ischemic tissues is a critical feature in EPC-mediated
neovascularization. As VEGF and SDF-1a are known
chemoattractant for EPCs, we evaluated the expression
pattern of these cytokines in response to DBcAMP. Our data
indicating an increased expression of both these cytokines,
both at mRNA and protein (histochemically) level and
enhanced EPC homing to the DBcAMP-treated diabetic
wounds, thus suggest that DBcAMP-induced augmentation
of VEGF and SDF-1 a provide critical signals for EPC homing
and their participation in the process of wound healing.
Several types of cells are known to produce VEGF and SDF-
1a in response to stimuli encountered in tissue microenvir-
onment. Our data showing that the protein expression of
VEGF and SDF-1a in the wounds was colocalized in
monocyte/macrophage lineage cells as well as in cells other
than monocyte/macrophages thus support this notion. As
mentioned above, VEGF and SDF-1 (which are chemokines
for EPC) are both upregulated by hypoxia or tissue injury,
after which EPC are mobilized and recruited to the sites
of regeneration where these factors are being produced. It
should be noted, however, that other factors such as
inflammatory cytokines produced in response to injury might
also enhance the expression of these angiogenic cytokines.
We therefore confirmed the specific contribution of DBcAMP
in the upregulation of these cytokines, in vitro. Studies
confirmed that in macrophages and fibroblasts, DBcAMP
treatment not only attenuated the high glucose-mediated
inhibition of VEGF an SDF-1a mRNA expression but also
enhanced their expression compared to control cells,
suggesting that mechanisms of enhanced neovascularization
and wound healing in response to DBcAMP involve at least,
in part, enhanced expression of these cytokines. Other studies
have also shown that transcription of VEGF or other
cytokines, which depend on the cAMP/protein kinase A
pathway, is usually upregulated from 4 to 24 hours after
stimulation with DBcAMP (Cheng et al., 1998; Pueyo et al.,
1998). Accordingly, the stimulatory effects of DBcAMP on
the production of VEGF and SDF-1 by fibroblasts might likely
be mediated by a cAMP/protein kinase A-dependent path-
way. In ischemic tissues, SDF-1 expression usually shows a
vascular and perivascular distribution, being mainly localized
to the endothelial cells, whereas little expression is reported
in smooth muscle cells, pericytes, and surrounding stromal
cells (Ceradini et al., 2004). However, very recently, it has
been reported that SDF-1 produced from dermal fibroblasts
increases keratinocyte proliferation (Florin et al., 2005).
Furthermore, as we mentioned above, several types of cells
including fibroblasts express SDF-1 in wound granulation
tissue. Taken together, it indicates that stromal cells including
fibroblasts might also be potential sources of SDF-1 when
wound healing is promoted by application of DBcAMP. It is
noteworthy that in our studies mRNA levels of SDF-1 in
macrophages were relatively low and SDF-1 protein expres-
sion could only be detected by immunofluorescence and
not as secreted proteins in ELISA. These data suggest the
possibility that macrophages are low producer of SDF-1 and
that they mostly act as the responder cells as they do express
SDF-1 receptor CXCR4 (Katschke et al., 2001), and contribute
to the SDF-1-induced VEGF expression. It still, however,
remains a possibility that macrophages might have a potential
to produce SDF-1, as the behavior of peritoneal macro-
phages, which we used in vitro studies, may not completely
resemble the biology of the wound site. We also evaluated
the mRNA expression of PDGF, also a known EPC
chemoattractant (Keswani et al., 2004); however, DBcAMP
did not influence PDGF mRNA levels either in fibroblasts or
in macrophages (data not shown).
Our data showing the ability of conditioned media from
fibroblasts or macrophages treated with DBcAMP to chemo-
attract EPC and attenuation of this process when neutralizing
antibodies to VEGF and/or SDF-1 were included in culture,
which further suggests DBcAMP-induced VEGF/SDF-1 as
a mediator of EPC function in wound healing. However, a
direct influence of DBcAMP on EPC is still unclear. Recent
studies have shown that cAMP mediates SDF-1-dependent
migration by upregulating surface expression of CXCR4
(the receptor for SDF-1) in several types of cells (Cole et al.,
1999; Kury et al., 2003). Such findings suggest that other
potential cytokines may also mediate DBcAMP effects in
wound healing.
In conclusion, DBcAMP accelerates wound healing in
diabetes, at least partly by upregulating angiogenic cytokines
VEGF and SDF-1, thereby promoting EPC recruitment and
vasculogenesis in wound granulation tissue. These observ-
ations may partly explain a mechanism by which DBcAMP
stimulates the clinical healing of skin ulcers, especially
in patients with impaired diabetic ulcer. Furthermore, our
data suggest that vascular remodeling induced by DBcAMP
might have therapeutic potential in not only skin wound
healing but also ischemic disorders such as myocardial or
limb ischemia.
MATERIALS AND METHODS
Animals
Genetically diabetic db/db mice were obtained from Clea Japan Inc.
(Japan). All procedures were performed in accordance with the
guidelines of the Animal Care and Use Committees of Kyoto
Prefectural University of Medicine.
Creation of wounds
Mice were between 8 and 12 weeks old at the time of study. The
animals were housed in individual cages, and wounds were created
as described previously (Greenhalgh et al., 1990) Briefly, after
induction of deep anesthesia by intraperitoneal injection of sodium
pentobarbital (160 mg/kg intraperitoneal), full-thickness excisional
skin wounds were made on the backs of the mice using a 6-mm
skin biopsy punch. Each wound was covered with a semipermeable
polyurethane dressing (OpSites, Smith and Nephew, Massillon,
OH). Twenty microliters of DBcAMP diluted with saline (102 M) or
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saline was applied every second day by injection through the Opsite
with a 27-G needle and was allowed to spread over the wound bed.
The application of DBcAMP or saline was continued up to the day of
wound harvest.
Monitoring of wound healing
A total of five db/db mice were examined at each time point. Wound
healing was monitored on days 1, 7, and 14 after wound creation.
Photographic images were analyzed using NIH Image software
by tracing the wound margin with a high-resolution mouse and
calculating the pixel area. Then, wound area data were compared
using the paired Student’s t-test.
Histological score
Wounds were resected after 14 days and a histological score was
assigned by examination in a blinded manner according to the
method described previously (Greenhalgh et al., 1990). Briefly, each
specimen was given a score between 1 and 12 as follows: 1–3, none
to minimal cell accumulation and granulation tissue or epithelial
migration; 4–6, thin, immature granulation dominated by inflamma-
tory cells but with few fibroblasts, capillaries, or collagen deposition
and minimal epithelial migration; 7–9, moderately thick granulation
tissue, ranging from domination by inflammatory cells to more
fibroblasts and collagen deposition; and 10–12, thick, vascular
granulation tissue dominated by fibroblasts and extensive collagen
deposition.
Immunofluorescence staining
For fluorescence analysis of wound vascularity, before being killed
animals were perfused with Rhodamine-conjugated BS1 lectin
(Sigma, St Louis, MO) 7 or 14 days after creation of wounds. The
animals were then perfused with phosphate-buffered saline and
vasculature was in vivo fixed by perfusing with 4% paraformalde-
hyde. The wounds were then harvested from the dorsum of the
animals and sectioned. Sections were stained with rat anti-CD31
antibody (1:100) (BD Biosciences, San Jose, CA). Green fluorescence
was generated by labeling with FITC–streptavidin (Vector Labora-
tories, Burlingame, CA) and biotinylated anti-rat antibody (Vector
Laboratories). Wound vascularity was analyzed by calculating the %
fluorescent area (CD31), as described previously (Jacobi et al.,
2002). Immunofluorescence double staining of F4/80 and VEGF or
SDF-1a were performed on frozen sections (6-mm thick). Sections
were stained with rat anti-F4/80 antibody (1:250) (Caltag Labo-
ratories, Burlingame, CA) and rabbit anti-VEGF antibody (1:400)
(Santa Cruz) or rabbit anti-SDF-1a antibody (1:200) (Torrey Pines
Biolabs, Houston, TX). Normal rabbit IgG (Santa Cruz) and normal
rat IgG (BD Biosciences) were used as isotype controls. Green
fluorescence was generated by labeling with FITC–streptavidin
(Vector Laboratories) and biotinylated anti-rat antibody (Vector
Laboratories). Red fluorescence was generated with Cy3-conjugated
anti-rabbit antibody (Vector Laboratories).
Transplantation of ex vivo-expanded EPC
Just after wounding, 1 106 EPC taken from db/db mice were
injected intravenously. To evaluate the accumulation of EPC at the
wound site, the cells were labeled with 1,10 –dioctadecyl –3,3,30,30 –
tetramethylindocarbocyanine – labeled acetylated low-density lipo-
protein (Biomedical Technologies, Stoughton, MA), as described
previously (Yamaguchi et al., 2003). Wounds were harvested on day
7 and embedded for cutting of frozen sections, which were stained
with an anti-CD31 antibody as described above. A total of 20
different granulation tissue fields (four sections from each animal)
were selected, and the CD31þ (DiI-labeled) EPCs were counted
at  100 magnification.
Cell culture
Fibroblasts were isolated from db/db mouse. After removal
of epidermal keratinocytes, fibroblasts were digested from the
dermal skin layer using 5% collagenase for 30 minutes. Culture
was performed in DMEM (Gibco, Grand Island, NY) containing 10%
fetal bovine serum (FBS). The explants were grown to confluence
and were passaged. After the first passage, fibroblasts were grown in
low-glucose-containing media (5 mM) or high-glucose-containing
media (35 mM) (D-glucose; Sigma, St Louis, MO). As a control for the
osmotic pressure of the high glucose concentrations, D-mannitol
(Sigma, St Louis, MO) was added in low-glucose-containing media
(5 mM D-glucose plus 30 mM D-mannitol). Fibroblasts were cultured
in hyperglycemic medium for 20 days before each experiment.
Fibroblast cultures used in this experiment ranged from five to
10 passages.
Ex vivo expansion of EPC was performed as described before
(Mallat et al., 2002). In brief, bone marrow cells obtained by flushing
the tibia and femur of db/db mouse were plated on rat plasma
vitronectin-coated (Sigma, St Louis, MO) culture dishes and
maintained in endothelial cell basal medium-2 (Cambrex, East
Rutherford, NJ) supplemented with 5% FBS, human VEGF-A, human
fibroblast growth factor-2, human epidermal growth factor, insulin-
like growth factor-1, and ascorbic acid. After 4 days of culture, non-
adherent cells were removed by washing, new medium was added,
and culture was continued until day 7.
Macrophages were isolated from the peritoneal cavity of db/db
mouse using thioglycollate, as described previously (Stein and
Gordon, 1991). Briefly, 4 days after the intraperitoneal injection of
3 ml of thioglycollate, macrophages were harvested from the
peritoneal cavity and cultured in RPMI 1640 medium (Cambrex)
containing 10% FBS with low-glucose-containing-media (5 mM D-
glucose plus 30 mM D-mannitol) or high-glucose-containing-media
(35 mM D-glucose) for 4 days before each experiment.
Quantitative real-time RT-PCR
Skin samples were harvested 0, 1, 4, and 7 days after surgery and
homogenized in RNA-Stat (Tel-Test Inc., Friendswood, TX). RNA
was isolated according to the manufacturer’s instructions.
For in vitro studies, fibroblasts and macrophages were cultured in
the absence or presence of various doses of DBcAMP and in low or
high glucose culture conditions. Cells were harvested after 6 or
24 hours and RNA was extracted using RNA-Stat according to
the manufacturer’s instructions. Total RNA was reverse transcribed
using Taqman Mutiscribe RT Kit (Biosystems, Foster City, CA) and
amplification was performed on the Lightcycler (Roche, Indianapo-
lis, IN) with the following primers and probes: VEGF: forward – 50-
CATCTTCAAGCCGTCCTGTGT-30; reverse, 50-CAGGGCTTCATCG
TTACAGCA-30 and FAM-CCGCTGATGCGCTGTGCAGG-BHQ.
SDF-1a – forward, 50-CCTCCAAACGCATGCTTCA-30; reverse,
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50-CCTTCCATTGCAGCATTGGT-30 and FAM-CTGACTTCCGCTTCT
CACCTCTGTAGCCT-TAMRA. 18S – forward, 50-CGGGTCGGGAG
TGGGT-30; reverse, 50-GAAACGGCTACCACATCCAAG-30 and
FAM-TTTGCGCGCCTGCTGCCTT-BHQ. The relative level of
expression of the target gene mRNAs was calculated by the
comparative CT method, with normalization for the control gene,
18s. Differences of CT values were calculated for each mRNA by
taking the mean value from duplicate reactions and subtracting the
mean value of 18s RNA. The fold change in the expression of each
target gene by treated cells relative to control cells was calculated
as: relative expression¼ 2DCT .
Preparation of CM
Fibroblasts or macrophages were incubated in 35 mm dishes with
10% FBS/DMEM or 10% FBS/RPMI 1640, respectively, until
subconfluent, and were washed in phosphate-buffered saline. Then
low- or high-glucose-conditioned DMEM or RPMI 1640 containing
104, 105, or 106 M DBcAMP without FBS was added to the
dishes, and supernatants were collected after culture for 48 hours.
Normal low-glucose-conditioned culture medium and supernatant
from cultures without DBcAMP were used as the controls. The CM
thus obtained was subjected to ELISA and was used for the EPC
migration assay.
ELISA for VEGF
ELISAs for VEGF and SDF-1 were performed using commercially
available from R&D Systems (Minneapolis, Minnesota, USA)
following the manufacturer’s protocol.
Migration assay
EPC migration was evaluated using a modified Boyden’s chamber
assay, essentially as described previously, using VEGF and/or SDF-1
as chemoattractants. (Schratzberger et al., 2000). To neutralize the
bioactivity of VEGF or SDF-1a, CM were preincubated with anti-
mouse VEGF antibody (0.2 mg/ml) (R&D Systems) or anti-mouse
SDF-1a antibody (100mg/ml) (R&D Systems) for 30 minutes at room
temperature. Migration was evaluated by counting the mean number
of migrating cells in five high-power fields (original magnification
 40) per chamber.
Statistical analysis
All results are presented as the mean7SEM. Statistical comparisons
between two groups were performed by Student’s t-test and analysis
of variance was used for serial analyses, with Po0.05 being
considered to indicate statistical significance. All of the in vitro
experiments were repeated at least three times.
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